LAVAL, QC, Aug. 30, 2018 /CNW/ - BELLUS Health Inc. (TSX:
BLU) ("BELLUS Health" or the "Company"), a clinical-stage
biopharmaceutical company developing novel therapeutics for
conditions with high unmet medical need, today announced that
Roberto Bellini, BELLUS Health's
President and Chief Executive Officer, will present a corporate
overview of the Company, including its lead program BLU-5937 for
the treatment of chronic cough, on Thursday
September 6, 2018 at 2:00 pm
ET at the Baird 2018 Global Healthcare Conference in
New York.
The presentation will be webcast live at
http://wsw.com/webcast/baird52/blu.to/ and archived for
90 days after the event. To ensure a timely connection to the
live webcast it is recommended that users register at least 15
minutes prior to the scheduled start time.
Following the event, the archived webcast and BELLUS Health's
presentation will be available on the Company's website at
www.bellushealth.com.
About the Conference
The Baird 2018 Global Healthcare Conference will be held at the
InterContinental New York Barclay Hotel in New York on September
5 and 6, 2018. This conference brings institutional and
private equity investors together with senior management from over
90 public and privately-held companies. The conference will feature
companies across the following sectors: Biotechnology, Healthcare
Supply Chain & Pharma Services, Healthcare Information
Technology, Life Sciences & Diagnostics, Medical Technology and
Facilities & Services.
About BELLUS Health (www.bellushealth.com)
BELLUS Health is a clinical-stage biopharmaceutical company
developing novel therapeutics for conditions with high unmet
medical need. Its pipeline of projects includes the Company's lead
drug candidate BLU-5937 for chronic cough and several other
partnered clinical-stage drug development programs. BLU-5937, a
highly selective P2X3 antagonist, has the potential to be a
best-in-class therapeutic for chronic cough patients who do not
respond to current therapies.
Chronic cough is a cough that lasts more than eight weeks and is
associated with significant adverse social, psychosocial and
physical effects on quality of life. A recent commercial assessment
performed by Torreya Insights on behalf of the Company concluded
that, in the United States alone,
more than 26 million adults have chronic cough and more than
2.6 million of these patients suffer from refractory chronic cough
lasting for more than a year.
SOURCE BELLUS Health Inc.